Mahon MF - Search Results

1

Small Molecule Antagonists of NAADP-Induced Ca²⁺ Release in T-Lymphocytes Suggest Potential Therapeutic Agents for Autoimmune Disease.

Zhang B, Watt JM, Cordiglieri C, Dammermann W, Mahon MF, Flügel A, Guse AH, Potter BVL. Zhang B, et al. Among authors: mahon mf. Sci Rep. 2018 Nov 13;8(1):16775. doi: 10.1038/s41598-018-34917-3. Sci Rep. 2018. PMID: 30425261 Free PMC article.

2

Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: x-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5(10)-estratriene.

Hejaz HA, Purohit A, Mahon MF, Reed MJ, Potter BV. Hejaz HA, et al. Among authors: mahon mf. J Med Chem. 1999 Aug 12;42(16):3188-92. doi: 10.1021/jm980717l. J Med Chem. 1999. PMID: 10447965

3

Bicyclic analogues of D-myo-inositol 1,4,5-trisphosphate related to adenophostin A: synthesis and biological activity.

Riley AM, Correa V, Mahon MF, Taylor CW, Potter BV. Riley AM, et al. Among authors: mahon mf. J Med Chem. 2001 Jun 21;44(13):2108-17. doi: 10.1021/jm0005499. J Med Chem. 2001. PMID: 11405648

4

D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase.

Fischer DS, Woo LW, Mahon MF, Purohit A, Reed MJ, Potter BV. Fischer DS, et al. Among authors: mahon mf. Bioorg Med Chem. 2003 Apr 17;11(8):1685-700. doi: 10.1016/s0968-0896(03)00042-7. Bioorg Med Chem. 2003. PMID: 12659755

5

A definitive synthesis of D-myo-inositol 1,4,5,6-tetrakisphosphate and its enantiomer D-myo-inositol 3,4,5,6-tetrakisphosphate from a novel butane-2,3-diacetal-protected inositol.

Mills SJ, Riley AM, Liu C, Mahon MF, Potter BV. Mills SJ, et al. Among authors: mahon mf. Chemistry. 2003 Dec 15;9(24):6207-14. doi: 10.1002/chem.200305207. Chemistry. 2003. PMID: 14679531

6

Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.

Lawrence HR, Vicker N, Allan GM, Smith A, Mahon MF, Tutill HJ, Purohit A, Reed MJ, Potter BV. Lawrence HR, et al. Among authors: mahon mf. J Med Chem. 2005 Apr 21;48(8):2759-62. doi: 10.1021/jm049045r. J Med Chem. 2005. PMID: 15828812

7

A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.

Leese MP, Hejaz HA, Mahon MF, Newman SP, Purohit A, Reed MJ, Potter BV. Leese MP, et al. Among authors: mahon mf. J Med Chem. 2005 Aug 11;48(16):5243-56. doi: 10.1021/jm050066a. J Med Chem. 2005. PMID: 16078843

8

E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.

Fischer DS, Allan GM, Bubert C, Vicker N, Smith A, Tutill HJ, Purohit A, Wood L, Packham G, Mahon MF, Reed MJ, Potter BV. Fischer DS, et al. Among authors: mahon mf. J Med Chem. 2005 Sep 8;48(18):5749-70. doi: 10.1021/jm050348a. J Med Chem. 2005. PMID: 16134943

9

Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.

Allan GM, Lawrence HR, Cornet J, Bubert C, Fischer DS, Vicker N, Smith A, Tutill HJ, Purohit A, Day JM, Mahon MF, Reed MJ, Potter BV. Allan GM, et al. Among authors: mahon mf. J Med Chem. 2006 Feb 23;49(4):1325-45. doi: 10.1021/jm050830t. J Med Chem. 2006. PMID: 16480268

10

Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.

Vicker N, Lawrence HR, Allan GM, Bubert C, Smith A, Tutill HJ, Purohit A, Day JM, Mahon MF, Reed MJ, Potter BV. Vicker N, et al. Among authors: mahon mf. ChemMedChem. 2006 Apr;1(4):464-81. doi: 10.1002/cmdc.200500087. ChemMedChem. 2006. PMID: 16892382

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

285 results

Search Page

Filters